Stroke is one of the leading causes of death in the United States. Limitations of currently available stroke treatment include a 3 hour time window for recombinant tissue plasminogen activator. Stem cells have become promising for the treatment of a variety of neurodegenerative diseases, including stroke. Therapies in this category include stimulation of endogenous neurogenesis, as well as the delivery of exogenous stem cells.This thesis focuses on the investigation of the intravenous delivery of a CD34 negative subset of umbilical cord blood stem cells as a therapy for stroke. Methods employed for this investigation include next generation sequencing technologies for gene expression profiling, 19-fluorine tracking of stem cells with MRI, and fluorescence biodistribution tracking.
University of Minnesota M.S. thesis. May 2013. Major: Stem cell biology. Advisor: Andrew Grande. 1 computer file (PDF); iv, 54 pages.
Investigation of intravenous administration of non-hematopoietic umbilical cord blood cells as a therapy for stroke.
Retrieved from the University of Minnesota Digital Conservancy,
Content distributed via the University of Minnesota's Digital Conservancy may be subject to additional license and use restrictions applied by the depositor.